Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

10X Genomics Inc (TXG)

10X Genomics Inc (TXG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,857,812
  • Shares Outstanding, K 127,752
  • Annual Sales, $ 642,820 K
  • Annual Income, $ -43,540 K
  • EBIT $ -61 M
  • EBITDA $ -17 M
  • 60-Month Beta 2.20
  • Price/Sales 4.50
  • Price/Cash Flow N/A
  • Price/Book 3.63

Options Overview Details

View History
  • Implied Volatility 91.61% (+3.81%)
  • Historical Volatility 62.78%
  • IV Percentile 79%
  • IV Rank 53.27%
  • IV High 127.16% on 04/23/25
  • IV Low 51.09% on 08/21/25
  • Expected Move (DTE 15) 2.64 (12.18%)
  • Put/Call Vol Ratio 0.15
  • Today's Volume 110
  • Volume Avg (30-Day) 722
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 10,012
  • Open Int (30-Day) 8,680
  • Expected Range 19.01 to 24.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.25
  • Number of Estimates 8
  • High Estimate -0.07
  • Low Estimate -0.41
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +30.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.26 +25.38%
on 02/12/26
23.30 -7.12%
on 03/03/26
+3.94 (+22.26%)
since 02/05/26
3-Month
15.18 +42.56%
on 12/15/25
23.56 -8.15%
on 01/23/26
+3.87 (+21.78%)
since 12/05/25
52-Week
6.78 +219.17%
on 04/07/25
23.56 -8.15%
on 01/23/26
+10.71 (+97.99%)
since 03/05/25

Most Recent Stories

More News
3 Stocks Under $50 We’re Skeptical Of

3 Stocks Under $50 We’re Skeptical Of

TXG : 21.64 (-3.26%)
SBH : 15.25 (-1.17%)
PEGA : 47.30 (+0.53%)
10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference

PLEASANTON, Calif. , Feb. 19, 2026 /PRNewswire/ -- 10x Genomics, Inc.  (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate...

TXG : 21.64 (-3.26%)
5 Must-Read Analyst Questions From 10x Genomics’s Q4 Earnings Call

5 Must-Read Analyst Questions From 10x Genomics’s Q4 Earnings Call

TXG : 21.64 (-3.26%)
3 Volatile Stocks We Steer Clear Of

3 Volatile Stocks We Steer Clear Of

TXG : 21.64 (-3.26%)
ASLE : 7.32 (-3.30%)
WFC : 82.11 (-2.17%)
Why Is 10x Genomics (TXG) Stock Soaring Today

Why Is 10x Genomics (TXG) Stock Soaring Today

TXG : 21.64 (-3.26%)
TXG Q4 Deep Dive: Consumables Growth, Spatial Expansion, and AI-Driven Demand Shape Outlook

TXG Q4 Deep Dive: Consumables Growth, Spatial Expansion, and AI-Driven Demand Shape Outlook

TXG : 21.64 (-3.26%)
10x Genomics (NASDAQ:TXG) Delivers Impressive Q4 CY2025

10x Genomics (NASDAQ:TXG) Delivers Impressive Q4 CY2025

TXG : 21.64 (-3.26%)
10x Genomics: Q4 Earnings Snapshot

10x Genomics: Q4 Earnings Snapshot

TXG : 21.64 (-3.26%)
10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026

PLEASANTON, Calif. , Feb. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full...

TXG : 21.64 (-3.26%)
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect

10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect

TXG : 21.64 (-3.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

10x Genomics Inc. is a life science technology company. It develops and sells instruments, consumables and software for analyzing biological systems. 10x Genomics Inc. is based in Pleasanton, California.

See More

Key Turning Points

3rd Resistance Point 23.79
2nd Resistance Point 23.44
1st Resistance Point 22.91
Last Price 21.64
1st Support Level 22.02
2nd Support Level 21.67
3rd Support Level 21.14

See More

52-Week High 23.56
Last Price 21.64
Fibonacci 61.8% 17.15
Fibonacci 50% 15.17
Fibonacci 38.2% 13.19
52-Week Low 6.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar